ClinicalTrials.gg
RecruitingNCT07085702Updated Aug 11, 2026

A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of the GSK 4-component Strep A Vaccine With Aluminum Hydroxide (Alum) or AS37 in Healthy Young Adults

A Phase 1 interventional study of Low dose Strep A Alum and Medium dose Strep A Alum in Streptococcal Infections, sponsored by GlaxoSmithKline. Recruiting at 2 sites in Australia. Open to participants aged 18 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Prevention

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 64 studies in Streptococcal Infections by GlaxoSmithKline — 1 open to participants now, 1 under way, none of them phase 3. Streptococcal Infections · GlaxoSmithKline.

Planned enrollment
50th of 55
108 · median 365
Started
2025
the only one that year
Phase 1
5 of 64
1 open now
Registered
64th of 64
by date

Among the 64 studies in Streptococcal Infections by GlaxoSmithKline, this one is the 50th largest by planned enrollment of the 55 interventional ones that give a count, is the only one that started in 2025, is one of 5 in phase 1, and was the 64th registered.

Streptococcal Infections

147 studies on the registry are indexed under Streptococcal Infections; 14 are open to participants now.

Browse Streptococcal Infections studies →

Open to participants now

1 of the 64 studies in Streptococcal Infections by GlaxoSmithKline is open now, in 1 country.

By country, each count listing its studies:

Who these studies take

Of the 10 Streptococcal Infections studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 25 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Streptococcal Infections by GlaxoSmithKline, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety of 3 doses of 2 new Strep A vaccine formulations, one with an Alum adjuvant, and the other with AS37 adjuvant. The Strep A vaccine will be tested for the first time in humans, in healthy young adults 18 to 25 years of age. The study will also assess if the vaccines have any immediate reactions and if they induce an immune response. A low, medium, and high dose of each formulation of the vaccine will be assessed in sequence.

03

Conditions studied

  • Streptococcal Infections

Keywords

  • Strep A
  • Streptococcus pyogenes
  • Safety
  • Reactogenicity
  • Immunogenicity
  • Healthy Adults
  • Australia
04

Who can participate

Ages eligible
18 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants, who, in the opinion of the Investigator, can and will comply with the requirements of the protocol (e.g., completion of electronic diaries [eDiaries], return for follow-up visits).
  • Written or witnessed/thumb-printed obtained from the participant prior to performance of any study-specific procedure.
  • Healthy participants as established by medical history, clinical examination, and laboratory assessments.
  • Satisfies all screening requirements.
  • Male and female participants between and including 18 and 25 years of age at the time of informed consent.
  • Female participants of nonchildbearing potential may be enrolled in the study. Nonchildbearing potential is defined as premenarche, , or had current bilateral tubal ligation or occlusion, hysterectomy, or bilateral ovariectomy.
  • Female participants who are of may be enrolled in the study if the participant:

    • has practiced adequate for 1 month prior to study intervention administration, and
    • has a negative pregnancy test on the day of study intervention administration, and
    • has agreed to continue adequate contraception during the entire study intervention administration period and for 1 month after completion of the study intervention administration series.
  • Male participants who are sexually active with a female partner of childbearing potential are eligible to participate if they agree to have their partner use a highly effective method of contraception for 1 month prior to the first study intervention administration until 1 month after completion of the study intervention administration series.
  • Male participants must refrain from donating sperm for 1 month prior to the first study intervention administration until 1 month after completion of the study intervention administration series.
  • Participants seronegative for (HIV), , and at Screening.

Exclusion criteria

Exclusion Criteria:

  • History of rheumatic fever or rheumatic heart disease during the lifetime of the participant as confirmed during interview with the participant or as documented in medical records.
  • Recent history of pharyngitis in the last four (4) weeks will be excluded. These participants can be rescreened once the recent pharyngitis passes the 4-weeks period. Participants with symptoms of acute pharyngitis at Screening will be tested with a Strep A rapid antigen test. Those with positive results will be excluded.
  • Progressive, unstable, or uncontrolled clinical conditions.
  • History (known or suspected) of any reaction or likely to be exacerbated by any component of the study interventions.
  • Any confirmed or suspected or immunodeficient condition, based on medical history and physical examination.
  • Hypersensitivity (e.g., allergy) to medicinal products or medical equipment anticipated to be used in this study.
  • Clinical conditions that represents a for IM vaccination or blood draws.
  • Any behavioral or cognitive impairment or psychiatric disease that, in the opinion of the Investigator, may interfere with the participant's ability to participate in the study.
  • Acute disease and/or fever (defined as temperature >=38.0°C) at the time of enrollment.
  • Any Grade >=2 and/or hematological and/or biochemical laboratory abnormality.
  • Any echocardiographic/Doppler Echo findings consistent with carditis at Screening.
  • Recurrent history or uncontrolled neurological disorders or seizures.
  • Medical history or family history of disease and other pIMDs.
  • Family history of acute rheumatic fever.
  • Acute or chronic illness, or clinically significant pulmonary, cardiovascular, hepatic, or renal functional abnormality.
  • Any other clinical condition that might pose additional risk to the participant due to participation in the study.
  • Administration of long-acting immune-modifying drugs (e.g., infliximab) at any time prior to the administration of the first dose of study intervention(s) or planned administration during the study period.
  • Prior receipt of an experimental Strep A vaccine.
  • Use of any or nonregistered product (drug, vaccine, or medical device) other than the study interventions during the period starting 30 days before the first dose of study intervention (Day -30 to Day 1), or their planned use during the study period.
  • Receipt of a vaccine not foreseen by the study protocol administered during the period starting at 21 days before the first dose of study intervention (28 days before the first dose, in case of ) and ending after the last dose of study intervention administration.
  • Administration of immunoglobulins and/or any blood products or plasma derivatives, or bone marrow transplantation, during the period starting 3 months before administration of the first dose of study intervention(s) or planned administration during the study period.
  • Chronic administration (defined as >14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting 3 months prior to the first dose of study intervention. For , this means prednisone equivalent >=20 mg/day for adult participants. Inhaled, topical, intra-articular, and intranasal steroids are allowed.
  • Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention (drug, vaccine, or invasive medical device).
  • Pregnant or lactating female participant.
  • Participant who is planning to become pregnant or planning to discontinue precautions.
  • History of or current chronic alcohol consumption and/or drug abuse.
  • Any study personnel or their immediate dependents, family, or household members.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    Low dose Strep A Alum Group

    Participants randomized to receive 3 doses of Low dose Strep A Alum vaccine on Day 1, Day 31, and Day 121.

    Biological: Low dose Strep A Alum

  • Experimental
    Medium dose Strep A Alum Group

    Participants randomized to receive 3 doses of Medium dose Strep A Alum vaccine on Day 1, Day 31, and Day 121.

    Biological: Medium dose Strep A Alum

  • Experimental
    High dose Strep A Alum Group

    Participants randomized to receive 3 doses of High dose Strep A Alum vaccine on Day 1, Day 31, and Day 121.

    Biological: High dose Strep A Alum

  • Experimental
    Low dose Strep A AS37 Group

    Participants randomized to receive 3 doses of Low dose Strep A AS37 vaccine on Day 1, Day 31, and Day 121.

    Biological: Low dose Strep A AS37

  • Experimental
    Medium dose Strep A AS37 Group

    Participants randomized to receive 3 doses of Medium dose Strep A AS37 vaccine on Day 1, Day 31, and Day 121.

    Biological: Medium dose Strep A AS37

  • Experimental
    High dose Strep A AS37 Group

    Participants randomized to receive 3 doses of High dose Strep A AS37 vaccine on Day 1, Day 31, and Day 121.

    Biological: High dose Strep A AS37

  • Placebo comparator
    Strep A Alum Placebo Group

    Participants randomized to receive 3 doses of Strep A Alum Placebo on Day 1, Day 31, and Day 121.

    Drug: Strep A Alum Placebo

Interventions

  • BiologicalLow dose Strep A Alum

    Low dose Strep A Alum vaccine will be administered intramuscularly (IM)

  • BiologicalMedium dose Strep A Alum

    Medium dose Strep A Alum vaccine will be administered IM

  • BiologicalHigh dose Strep A Alum

    High dose Strep A Alum vaccine will be administered IM

  • BiologicalLow dose Strep A AS37

    Low dose Strep A AS37 vaccine will be administered IM

  • BiologicalMedium dose Strep A AS37

    Medium dose Strep A AS37 vaccine will be administered IM

  • BiologicalHigh dose Strep A AS37

    High dose Strep A AS37 vaccine will be administered IM

  • DrugStrep A Alum Placebo

    Strep A Alum Placebo will be administered IM

06

What researchers measure

Primary outcomes

  1. Number of participants with solicited administration site events

    Solicited administration-site events include pain, redness, and swelling at the administration site.

    Time frame: Up to 7 days after each study intervention administration occurring at Day 1, Day 31, and Day 121

  2. Number of participants with solicited systemic events

    Solicited systemic events include fever, headache, myalgia (muscle pain), arthralgia (joint pain), and fatigue (tiredness). Fever is defined as body temperature equal to or above 38.0°C. The preferred location for measuring temperature is the axilla.

    Time frame: Up to 7 days after each study intervention administration occurring at Day 1, Day 31, and Day 121

  3. Number of participants with unsolicited adverse events (AEs)

    An unsolicited AE is an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. Unsolicited AEs include both serious and nonserious AEs.

    Time frame: Up to 30 days after each study intervention administration occurring at Day 1, Day 31, and Day 121

  4. Number of participants with laboratory abnormalities

    Time frame: 7 days after each study intervention administration at Day 8, Day 38, and Day 128

  5. Number of participants with adverse events of special interest (AESIs)

    AESIs include potential immune-mediated disorders (pIMDs) and rheumatic carditis.

    Time frame: From Day 1 to Day 301

  6. Number of participants with serious adverse events (SAEs)

    An SAE is defined as any untoward medical occurrence that results in death, is life threatening, requires hospitalization or prolongs existing hospitalization, results in disability/incapacity, abnormal pregnancy outcomes, or other medically significant events.

    Time frame: From Day 1 to Day 301

  7. Number of participants with AEs leading to withdrawal from the study or to discontinuation of study vaccine

    Time frame: From Day 1 to Day 301

Secondary outcomes

  1. Geometric mean concentrations of immunoglobulin G (IgG) against Streptolysin O (SLO), S. pyogenes Cell Envelope Protease (SpyCEP), S. pyogenes Adhesion and Division protein (SpyAD), and Group A Carbohydrate (GAC), as measured by multiplex immunoassay

    Time frame: Before each study intervention (Day 1, Day 31, and Day 121), 30 days after each study intervention (Day 31, Day 61, and Day 151), and 7 days and 6 months after the third study intervention administration (Days 128 and 301, respectively)

  2. Geometric mean fold increase of IgG against SLO, SpyCEP, SpyAD, and GAC, as measured by multiplex immunoassay

    Time frame: 30 days after each study intervention administration compared to before each study intervention administration (Day 31 versus Day 1, Day 61 versus Day 31, and Day 151 versus Day 121) and to before study intervention administration (Day 1)

  3. Number of participants with greater than or equal to (>=) 2-fold and >=4 fold increase in IgG antibody concentration against SLO, SpyCEP, SpyAD, and GAC, as measured by multiplex immunoassay

    Time frame: 30 days after each study intervention administration (Day 31, Day 61, and Day 151) compared to before study intervention administration (Day 1)

07

Study locations

2 of 2 sites recruiting
  • GSK Investigational Site
    Botany, New South Wales 2019, Australia
    Recruiting
  • GSK Investigational Site
    Camberwell, Victoria 3124, Australia
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Jun 2027, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2025
First posted
Jul 25, 2025
StartActual
Jul 29, 2025
Primary completionEst.
Jun 29, 2027
CompletionEst.
Jun 29, 2027
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07085702
Lead sponsor
GlaxoSmithKline
Collaborators
HHS/BARDA, Wellcome Trust, DHSC/GAMRIF, Germany/BMBF, DG HERA (kfW)
Responsible party
Sponsor
First posted
Jul 25, 2025
Start date
Jul 29, 2025
Primary completion
Jun 29, 2027 (estimated)
Completion
Jun 29, 2027 (estimated)
Last update
Aug 11, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466
King C Cheung
principal investigator · Emeritus Research
Juliet Freeborn
principal investigator · Emeritus Research

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion